Scout Bio develops one-time adeno-associated viral (AAV) gene therapies to induce long-term expression of therapeutic proteins in pets, specifically targeting chronic conditions such as anemia associated with chronic kidney disease in cats. The company addresses the lack of FDA-approved treatments for these conditions by providing a single injection solution that offers sustained clinical benefits and improved owner compliance.
Funding
$33M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many chronic conditions in pets lack effective, long-lasting treatments, leading to frequent vet visits and inconsistent owner compliance with medication schedules. Current treatments often fail to address the underlying causes of disease, providing only symptomatic relief and potentially causing adverse side effects.
Solution
Scout Bio develops one-time gene therapies and monoclonal antibodies designed to provide sustained therapeutic protein expression in pets, addressing major chronic health conditions with a single administration. Utilizing adeno-associated viral (AAV) vector technology, their therapies aim to deliver long-term clinical benefits, improve owner compliance, and enhance the overall standard of care in veterinary medicine. By focusing on chronic illnesses where the sustained expression of a single functional protein can yield significant clinical benefits, Scout Bio offers a convenient and effective approach to disease management in pets. Their lead therapy targets anemia associated with chronic kidney disease (CKD) in cats, a common and progressive condition with limited FDA-approved treatments.
Target Audience
The primary target audience includes veterinarians seeking innovative and long-lasting treatments for chronic conditions in pets, as well as pet owners looking for convenient and effective solutions to improve their animals' quality of life.
Features
- One-time gene therapies using AAV vector technology for sustained therapeutic protein expression
- Focus on chronic conditions such as anemia associated with CKD in cats, osteoarthritis pain, and diabetes
- Intramuscular injection for convenient administration and integration into veterinary practice
- Vectorized antibody approach for long-term production of therapeutic antibodies
- Novel GLP-1 analog expressed via AAV gene therapy for feline diabetes
- Proprietary AAV vector capsids optimized for enhanced manufacturability and muscle cell targeting
- Development of monoclonal antibodies (mAbs) for chronic pain management